Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88606 | 1.00 | EGFR (0.58) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| Hydrochloric Acid SCHEMBL30749417 | 0.98 | EGFR (0.56) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| Hydrochloric Acid SCHEMBL30749407 | 0.98 | EGFR (0.56) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| Formic Acid SCHEMBL30064211 | 0.88 | EGFR (0.47) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| SCHEMBL29409337 | 0.83 | EGFR (0.60) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| SCHEMBL137377 | 0.83 | EGFR (0.60) | EGFRMKNK2CSNK1DCSNK1ECLK1 | |
| SCHEMBL1533934 | 0.82 | EGFR (0.55) | EGFRMKNK2CLK1PIK3CDPIK3CA | |
| Trifluoroacetic Acid SCHEMBL30749397 | 0.82 | EGFR (0.42) | EGFRKDM4C | |
| Isoquinoline SCHEMBL15549866 | 0.81 | EGFR (0.77) | EGFRMKNK2CLK1PIK3CDPIK3CA | |
| Hydrochloric Acid SCHEMBL322987 | 0.81 | EGFR (0.58) | EGFRMKNK2CSNK1DCSNK1ECLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-110036012-B | Pyrido [3,4-d ] pyrimidine derivatives and pharmaceutically acceptable salts thereof | 帝人制药株式会社 | 2022-05-10 | — | — | CN | claimed |
| CN-114085220-A | Substituted morpholine-4-carboxylic ester derivatives, their compositions and their medical use | 上海海雁医药科技有限公司 | 2022-02-25 | — | — | CN | claimed |
| WO-2026107076-A1 | CDK2 INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4105213-B1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME | PHAROS IBIO CO LTD (KR) | 2026-04-15 | — | — | EP | disclosed |
| EP-4105213-B1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME | PHAROS IBIO CO LTD (KR) | 2026-04-15 | — | — | EP | disclosed |
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | disclosed |
| CN-120091811-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025103502-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-110036012-B | Pyrido [3,4-d ] pyrimidine derivatives and pharmaceutically acceptable salts thereof | 帝人制药株式会社 | 2022-05-10 | — | — | CN | disclosed |
| WO-2022075486-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2022-04-14 | — | — | WO | disclosed |
| EP-3976618-A1 | TRICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114269751-A | Optically pure oxaspiro-substituted pyrrolopyrazole derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114222737-A | Small molecule inhibitor of NF-kB induced kinase | 詹森药业有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114222743-A | Oxoaxamembered ring pyrimidine compounds, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11261182-B2 | Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof | TEIJIN PHARMA LIMITED (JP) | 2022-03-01 | — | — | US | disclosed |
| CN-114085220-A | Substituted morpholine-4-carboxylic ester derivatives, their compositions and their medical use | 上海海雁医药科技有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114026083-A | Heterocyclic inhibitors of tyrosine kinases | 德州大学系统董事会 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261182-B2 | Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof | CDK6, CDK4, CDKL4 | EGFR 3047/4885MKNK2 1093/4885CSNK1D 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.